Molecule intelOpportunity: Moderate0Crowded market

Alfacalcidol

112 brands · 89 companies · product forms

2 DRAP alerts

Opportunity snapshot

Launch attractiveness
39
Market saturation
92
Price room
100
Regulatory risk
70
112
brands
89
companies
Rs 427.5
median price
19
price points
87.03x
price spread
90
confidence %

Who competes here

Top companies by brand count — fragmented market (no dominant player) · leader share 5%

Price room

Across observed sources and strengths
CheapestRs 36
MedianRs 427.5
Most expensiveRs 3,133
Spread87.03×
Sources: DVAGO

max/min price ratio 87.03x across 19 trusted points (Rs 36.0-3133.0). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Brands & products on the market

Sample of 12 live products for Alfacalcidol — each links to its own medicine page.

Regulatory alerts

Recall exposurelatest 2026-04-14
19. Recall Alert – WHO Recall Class-II
Recall Alert: Drug Product; Oscal-D Tablets (Batch # 6904) by M/s Aries Pharmaceuticals (P

Why this score

Launch attractiveness

40% supply-gap(20) + 25% price-variation(100) + 20% low-competition(8) + 15% supply-disruption(40), damped by confidence(90). Higher = more attractive, less crowded opportunity.

Market saturation

89 canonical companies and 112 brands compete (saturation pegged at 30 companies / 150 brands).

Price room

max/min price ratio 87.03x across 19 trusted points (Rs 36.0-3133.0). NOTE: mixes strengths (graph prices carry no strength), so treat as indicative.

Regulatory risk

2 DRAP alert(s), latest 2026-04-14 incl. recall/safety.

Confidence

Reduced by: no ATC code.

Packaged brief for this moderate opportunity?

Molecule page + company profiles + price-room analysis are the pilot package for pharma teams.

See packaged reports All 3868 molecules

Molecule intelligence as of 2026-07-30. Brand/company counts from DRAP registry and observed retail sources.

For medicine intelligence and professional reference only. Not medical advice.